• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/19/25 4:20:47 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    false 0001140859 0001140859 2025-05-15 2025-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of Earliest Event Reported): May 15, 2025

     

    Cencora, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   1-16671   23-3079390
    (State or other jurisdiction   (Commission   (I.R.S. Employer
    of incorporation)   File Number)   Identification No.)
             

    1 West First Avenue
    Conshohocken, PA

         

     

    19428-1800

    (Address of principal executive offices)       (Zip Code)

     

    Registrant’s telephone number, including area code:   (610) 727-7000

     

    Not Applicable

    Former name or former address, if changed since last report

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which
    registered
    Common stock COR New York Stock Exchange (NYSE)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company     ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ¨

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On May 15, 2025, Cencora, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) by and among the Company, BNP PARIBAS, Citigroup Global Markets Limited, J.P. Morgan Securities plc and Société Générale on behalf of themselves and as representatives of the several underwriters named therein (the “Underwriters”). The Underwriting Agreement provides for the issuance and sale by the Company, and the purchase by the Underwriters, of €500,000,000 aggregate principal amount of the Company’s 2.875% Senior Notes due 2028 (the “2028 Notes”) and €500,000,000 aggregate principal amount of the Company’s 3.625% Senior Notes due 2032 (the “2032 Notes” and, together with the 2028 Notes, the “Notes”). The Notes will be senior unsecured obligations of the Company. The Underwriting Agreement contains representations, warranties, conditions and covenants of the parties thereto and provides for indemnification by each of the Company and the Underwriters against certain liabilities and contribution provisions in respect of those liabilities. Subject to the closing conditions specified in the Underwriting Agreement, the Company expects to consummate the sale of the Notes to the Underwriters on May 22, 2025.

     

    The offer and sale of the Notes have been registered under the Securities Act of 1933, as amended, pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-283481) (the “Shelf Registration Statement”), filed with the Securities and Exchange Commission on November 26, 2024, the prospectus dated November 26, 2024, and the related prospectus supplement dated May 15, 2025.

     

    If the sale of the Notes is consummated pursuant to the terms set forth in the Underwriting Agreement, the Company estimates that it will receive net proceeds of approximately €994.0 million (after deducting the underwriting discount and offering expenses) from the sale of the Notes. The Company intends to use the net proceeds of the offering for general corporate purposes. Pending application of the net proceeds from the sale of the Notes for the foregoing purposes, the Company expects to invest such proceeds in high-quality, short-term debt securities (although the Company is not required to do so by the terms of the Notes).

     

    Certain of the underwriters and their affiliates have in the past provided, and may in the future provide, investment banking, commercial banking, derivative transactions and financial advisory services to the Company and its affiliates in the ordinary course of business for which they have received and may continue to receive customary fees and commissions. Specifically, BNP PARIBAS, Citigroup Global Markets Limited, J.P. Morgan Securities plc, Société Générale and Wells Fargo Securities International Limited or their affiliates and certain other Underwriters have served as underwriters in connection with past senior note offerings by the Company and may serve similar roles in future securities offerings by the Company. Additionally, certain of the Underwriters or their affiliates also serve various roles in the Company’s multi-currency revolving credit facility dated as of October 9, 2024 (and may serve in similar roles in an amendment and restatement of our existing revolving credit agreement, if executed): JPMorgan Chase Bank, N.A., an affiliate of J.P. Morgan Securities plc, serves as administrative agent; JPMorgan Chase Bank, N.A., BNP Paribas Securities Corp., an affiliate of BNP PARIBAS, BofA Securities, Inc., an affiliate of Merrill Lynch International, Citibank, N.A., an affiliate of Citigroup Global Markets Limited and Wells Fargo Securities, LLC, an affiliate of Wells Fargo Securities International Limited, serve as joint lead arrangers and joint bookrunners; and BNP PARIBAS, Citibank, N.A., Bank of America N.A., an affiliate of Merrill Lynch International, and Wells Fargo Bank, National Association, an affiliate of Wells Fargo Securities International Limited, serve as syndication agents. In addition, Bank of America N.A. serves as a letter of credit lender under such facility. The Underwriters or their affiliates also serve various roles in the Company’s commercial paper program. Additionally, certain of the Underwriters or their affiliates also serve as lenders, agents and in other capacities under the Company’s other credit facilities. Certain of the Underwriters or their affiliates serve as lenders, agents and in other capacities under the Company’s existing term loan facility dated as of November 26, 2024 (and may serve in similar roles following the amendment of the Company’s term loan facility): Bank of America N.A. serves as administrative agent; BNP Paribas Securities Corp., Citibank, N.A., JPMorgan Chase Bank, N.A., BofA Securities, Inc. and Wells Fargo Securities, LLC serve as joint lead arrangers and joint bookrunners; and BNP PARIBAS, Citibank, N.A., JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association serve as syndication agents. Certain of the Underwriters or their affiliates serve as lenders, agents and in other capacities under the Company’s 364-day revolving credit facility dated as of November 26, 2024: Bank of America N.A. serves as administrative agent; BNP Paribas Securities Corp., Citibank, N.A., JPMorgan Chase Bank, N.A., BofA Securities, Inc. and Wells Fargo Securities LLC serve as joint lead arrangers and joint bookrunners; and BNP PARIBAS, Citibank, N.A., JPMorgan Chase Bank, N.A. and Wells Fargo Bank, National Association serve as syndication agents. Additionally, Société Générale serves as a lender under the Company’s uncommitted money market line credit agreement dated as of June 10, 2022, as amended February 3, 2025. In addition, U.S. Bancorp Investments, Inc., is an affiliate of the trustee, registrar and paying agent for the Notes.

     

     

     

     

    The foregoing is a brief description of certain terms of the Underwriting Agreement and, by its nature, is incomplete. It is qualified in its entirety by the text of the Underwriting Agreement filed as Exhibit 1.1 to this Current Report and incorporated herein by reference. The Underwriting Agreement is also filed with reference to, and is hereby made an exhibit to, the Shelf Registration Statement.

     

    Forward-Looking Statements

     

    Certain of the statements contained in this Current Report on Form 8-K are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act”). Words such as “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “sustain,” “synergy,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. A more detailed discussion of the risks and uncertainties that could cause the Company’s actual results to differ materially from those indicated is included in the “Risk Factors” and “Management’s Discussion and Analysis” sections in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and elsewhere in that report and other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit
    Number
      Description
    1.1   Underwriting Agreement, dated as of May 15, 2025, by and among Cencora, Inc., BNP PARIBAS, Citigroup Global Markets Limited, J.P. Morgan Securities plc and Société Générale, as representatives of the underwriters listed in Schedule 1 thereto.
         
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Cencora, Inc.
       
    May 19, 2025 By: /s/ James F. Cleary
        Name: James F. Cleary
        Title: Executive Vice President and Chief Financial Officer

     

     

     

    Get the next $COR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    12/9/2025$400.00Overweight
    Barclays
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    More analyst ratings

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Mauch Robert P. covered exercise/tax liability with 2,144 shares and converted options into 5,790 shares, increasing direct ownership by 6% to 69,392 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    11/24/25 5:15:42 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Chief Financial Officer Cleary James F converted options into 1,876 shares and covered exercise/tax liability with 824 shares, increasing direct ownership by 0.79% to 134,941 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    11/24/25 5:14:31 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Executive Vice President Campbell Elizabeth S converted options into 1,590 shares and covered exercise/tax liability with 736 shares, increasing direct ownership by 3% to 27,242 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    11/24/25 5:13:22 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    SEC Filings

    View All

    SEC Form 10-K filed by Cencora Inc.

    10-K - Cencora, Inc. (0001140859) (Filer)

    11/25/25 2:23:01 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    11/5/25 6:33:58 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form 144 filed by Cencora Inc.

    144 - Cencora, Inc. (0001140859) (Subject)

    10/1/25 10:36:13 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

    Revenue of $83.7 Billion for the Fourth Quarter, a 5.9 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $(1.75) and Adjusted Diluted EPS of $3.84 Revenue of $321.3 Billion for Fiscal Year 2025, a 9.3 Percent Year-Over-Year Increase Fiscal Year 2025 GAAP Diluted EPS of $7.96 and Adjusted Diluted EPS of $16.00 Company increases its quarterly dividend by 9 percent Company raises its long-term guidance expectations Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally a

    11/5/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

    Biomarker data, enhanced therapeutic data and insights will enable biopharmaceutical innovation and physician support through informed decision-making IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansion, IntrinsiQ is now also offering oncology biomarker data, enabling physicians to transition from a generalized treatment approach to precision medicine. This critical data allows physicians to tailor cancer therapies to the individual needs of each patient, helping to optimize treatment outcomes and advance the standard of car

    10/16/25 9:00:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access

    10/6/25 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/29/24 4:02:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Barclays initiated coverage on Cencora with a new price target

    Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $400.00

    12/9/25 8:43:35 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

    6/3/25 7:24:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Mizuho resumed coverage on Cencora with a new price target

    Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

    12/4/24 7:30:44 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    11/4/24 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

    The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

    9/14/21 2:00:00 PM ET
    $AXS
    $COR
    $POR
    Property-Casualty Insurers
    Finance
    Other Pharmaceuticals
    Health Care

    $COR
    Financials

    Live finance-specific insights

    View All

    Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

    Revenue of $83.7 Billion for the Fourth Quarter, a 5.9 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $(1.75) and Adjusted Diluted EPS of $3.84 Revenue of $321.3 Billion for Fiscal Year 2025, a 9.3 Percent Year-Over-Year Increase Fiscal Year 2025 GAAP Diluted EPS of $7.96 and Adjusted Diluted EPS of $16.00 Company increases its quarterly dividend by 9 percent Company raises its long-term guidance expectations Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally a

    11/5/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access

    10/6/25 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2025 Third Quarter Results

    Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below

    8/6/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cencora Inc.

    SC 13D/A - Cencora, Inc. (0001140859) (Subject)

    8/5/24 6:43:49 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

    SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

    7/12/21 8:29:18 AM ET
    $COR
    Other Pharmaceuticals
    Health Care